TABLE 5.
SBA GMTs, percentage of subjects with SBA titers of ≥4 and ELISA IgG GMCs against OMVs and opsonophagocytic GMTs against strain NZ98/254 before and after a booster dose
| Regimen | No. of subjects
|
SBA GMT (95% CI)
|
% Subjects with SBA titers of ≥4 (95% CI)
|
ELISA GMC (U/ml [95% CI])
|
Opsonophagocytic GMT (95% CI)
|
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| Before fourth dose | 6 wk after fourth dose | Before fourth dosea | 6 wk after fourth dose | Before fourth dose | 6 wk after fourth dose | Before fourth dose | 6 wk after fourth dose | Before fourth dose | 6 wk after fourth dose | |
| Four doses MenBvac | 6 | 6 | 2.5 (0.99-6.4) | 4.0 (1.3-12) | 50 (12-88) | 67 (22-96) | 148 (70-314) | 647 (360-1,162) | 4.5 (1.2-17) | 18 (7.3-44) |
| Three doses MenBvac + one dose MeNZB | 13 | 13 | 4.0 (2.1-7.6) | 20 (9.3-42) | 46 (19-75) | 85 (55-98) | 275 (165-458) | 1480 (994-2,204) | 11 (4.5-27) | 68 (37-124) |
| Four doses MeNZB | 5 | 5 | 3.5 (1.3-9.7) | 11 (3.1-36) | 40 (5-85) | 80 (28-99) | 214 (94-487) | 1,062 (559-2,018) | 11 (2.5-45) | 56 (21-149) |
| Three doses MeNZB + one dose MenBvac | 9 | 9 | 4.0 (1.9-8.6) | 14 (5.5-34) | 44 (14-79) | 78 (40-97) | 216 (117-398) | 1,954 (1,211-3,154) | 6.4 (2.2-19) | 81 (39-168) |
| Four doses combined vaccine | 19 | 19 | 2.1 (1.2-3.5) | 10 (5.5-19) | 26 (9-51) | 89 (67-99) | 271 (177-413) | 1,319 (949-1,833) | 8.3 (3.9-17) | 59 (36-98) |
a
The fourth dose was given as booster dose 1 year after the primary vaccination.